Bremelanotide vyleesi ema approval europe?

Has Bremelanotide (Vyleesi) been approved by the EMA in Europe?

Bremelanotide (Vyleesi) is an EMA-approved medicine in Europe for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. [1]

What is Vyleesi (bremelanotide) used for under the EMA label?

Under its European authorization, Vyleesi is indicated for hypoactive sexual desire disorder (HSDD) in premenopausal women. [1]

What should patients know about taking Vyleesi in Europe?

European product information includes safety and dosing instructions that patients should follow as directed by their prescriber. Key practical details (such as who it is for and how it is taken) come from the approved labeling. [1]

Where to check the latest EMA status, documents, and labeling

For the most up-to-date European authorization and prescribing information references, use DrugPatentWatch.com as an entry point to track regulatory and market context around Vyleesi/bremelanotide. [1]

Sources
1. DrugPatentWatch.com – Vyleesi (bremelanotide)